Amended Current Report Filing (8-k/a)
March 30 2021 - 5:23PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment
No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event reported): January 15,
2021
Tenax
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-34600
|
|
26-2593535
|
(State
or other jurisdiction of incorporation)
|
|
(CommissionFile
Number)
|
|
(IRS
EmployerIdentification No.)
|
ONE Copley Parkway, Suite 490
Morrisville, NC 27560
(Address
of principal executive offices) (Zip Code)
919-855-2100
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
Common
Stock, $0.0001 par value per share
|
TENX
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2).
Emerging growth
company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
EXPLANATORY NOTE
Tenax Therapeutics, Inc. (the “Company”) is filing this
Amendment No. 1 to Form 8-K (this “Amendment”) to amend
its Current Report on Form 8-K filed on January 19, 2021 (the
“Original Form 8-K”) with the Securities and Exchange
Commission (the “SEC”) disclosing, among other things,
the Company’s acquisition of PHPrecisionMed Inc.
(“PHPM”). The purpose of this Amendment is to provide
the financial information required under parts (a) and (b) of Item
9.01 of Form 8-K and amend and restate Item 9.01 of the Original
Form 8-K.
No other changes have been made to the Original Form 8-K. This
Amendment speaks as of the original filing date of the Original
Form 8-K, does not reflect events that may have occurred subsequent
to the original filing date, and, except as set forth herein, does
not modify or update in any way disclosures made in the Original
Form 8-K. This Amendment should be read in conjunction with the
Original Form 8-K.
Item 9.01 Financial Statements and
Exhibits.
(a) Financial Statements of Businesses
Acquired.
The audited historical financial statements of PHPM for the year
ended December 31, 2019 are filed as Exhibit 99.2 hereto and
incorporated herein by reference.
The unaudited financial statements of PHPM for the nine months
ended September 30, 2020 are filed as Exhibit 99.3 hereto and
incorporated herein by reference.
(b) Pro Forma Financial Information.
The unaudited pro forma condensed combined balance sheet and
statement of operations of the Company as of and for the nine
months ended September 30, 2020 and the unaudited pro forma
condensed combined statement of operations of the Company for the
year ended December 31, 2019 are filed as Exhibit 99.4 hereto and
incorporated herein by reference.
Exhibit No.
|
|
Description
|
|
|
Agreement
and Plan of Merger among PHPrecisionMed Inc., Tenax Therapeutics,
Inc., Life Newco II, Inc., and Dr. Stuart Rich dated January 15,
2021*
|
|
|
Certificate
of Designation of Series B Convertible Preferred
Stock*
|
|
|
Employment
Agreement with Dr. Stuart Rich dated January 15, 2021*
|
|
|
Consent
of Independent Registered Public Accounting Firm
|
|
|
Press
Release dated January 19, 2021*
|
|
|
Audited financial statements of PHPrecisionMed Inc. as of and for
the year ended December 31, 2019
|
|
|
Unaudited financial statements of PHPrecisionMed Inc. as of and for
the nine months ended September 30, 2020
|
|
|
Unaudited pro forma condensed combined financial information of the
Company as of and for the nine months ended September 30, 2020 and
the unaudited pro forma condensed combined statement of operations
of the Company for the year ended December 31, 2019
|
*Filed
with the Original From 8-K, which was filed with the SEC on January
19, 2021.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: March 30, 2021
|
Tenax Therapeutics, Inc.
|
|
|
|
|
|
|
|
|
By: /s/ Michael B. Jebsen
|
|
|
Michael
B. Jebsen
|
|
|
President
and Chief Financial Officer
|
|
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Apr 2023 to Apr 2024